Ventus Therapeutics Doses First Patient in Phase 2 Trial of VENT-03 cGAS Inhibitor for Lupus
核心洞察
Ventus Therapeutics (搜索) has dosed the first patient in a Phase 2 clinical trial of VENT-03, marking the most advanced oral small-molecule cGAS (搜索) inhibitor in clinical development.
The multicenter, randomized, double-blind, placebo-controlled trial will evaluate VENT-03's efficacy and safety in lupus (搜索) patients with active skin disease, targeting more than five million people living with lupus worldwide.
The study incorporates biomarkers for inflammation and cardiovascular health, with top-line results expected in the second half of 2026 from the 28-day placebo-controlled portion.
Ventus Therapeutics (搜索) has achieved a significant milestone by dosing the first patient in a Phase 2 clinical trial of VENT-03, a novel oral small-molecule cyclic GMP-AMP synthase (cGAS (搜索)) inhibitor, for the treatment of lupus (搜索). This marks the first oral small-molecule cGAS inhibitor to successfully complete a first-in-human Phase 1 study and advance to Phase 2 testing in patients.
The development addresses a substantial unmet medical need, as more than five million people worldwide live with lupus (搜索), a disease that presents significant burden with painful and often debilitating symptoms that can progress to multiple organ systems including the kidneys, heart, lungs, and brain. According to Dr. Mona Kotecha, Chief Medical Officer of Ventus, "Treatment choices remain limited, leaving significant unmet need."
Novel Mechanism of Action
VENT-03 targets the cGAS (搜索) pathway, which plays a prominent role in inflammation, cell senescence, and cell death. The cGAS protein is an intracellular pattern recognition receptor that becomes activated after binding to double-stranded DNA in the cytoplasm. This cytoplasmic DNA presence often results from cellular dysfunction, a hallmark of many autoimmune and inflammatory diseases.
When activated, cGAS (搜索) leads to cGAMP formation, activation of STING (搜索), pronounced inflammation, and tissue damage. The cGAS pathway has been demonstrated as a key driver of lupus (搜索) and other inflammatory diseases, including rheumatoid arthritis (搜索), systemic sclerosis (搜索), dermatomyositis (搜索), and Sjögren's disease (搜索), and is also implicated in cardiometabolic conditions and inflammaging.
Phase 2 Trial Design and Objectives
The Phase 2 study is designed as a multicenter, randomized, double-blind, placebo-controlled trial with an open-label extension, specifically targeting patients with lupus (搜索) who have active skin disease. The trial's key objectives include evaluating the safety and efficacy of VENT-03 in changing interferon-stimulated and inflammatory gene signatures in both blood and skin, while also assessing the drug's effect on clinical disease severity.
Additional objectives encompass evaluating VENT-03's impact on systemic disease activity using accepted systemic lupus (搜索) scales and measuring its effect on a comprehensive panel of biomarkers, including those assessing cardiac health and senescence. Dr. Kotecha emphasized that "our Phase 2 trial incorporates a robust panel of biomarkers, including general inflammation and cardiovascular biomarkers applicable to a broad range of diseases beyond lupus."
Timeline and Broader Implications
Top-line data from the 28-day placebo-controlled portion of the trial is expected in the second half of 2026, with data from the 2-month open-label extension to follow. The company positions VENT-03 as having the potential to become "a better and more convenient once-daily oral option for patients with limited available treatments."
Dr. Marcelo Bigal, President and CEO of Ventus, highlighted the broader therapeutic potential: "This Phase 2 study of VENT-03 marks an important step in our efforts to demonstrate the broad potential of cGAS (搜索) inhibition not only in lupus (搜索), but also in additional interferon-driven I&I diseases as well as cardiometabolic disorders and inflammaging."
Company Pipeline and Platform
VENT-03 was discovered using Ventus' proprietary ReSOLVE® platform and represents part of a robust pipeline of wholly-owned programs. The company's portfolio includes VENT-02, a brain-penetrant oral NLRP3 (搜索) inhibitor in Phase 2 for Parkinson's disease (搜索), and VENT-04, a first-in-class caspase-4/5 (搜索) inhibitor in preclinical development. Additionally, Ventus has out-licensed VENT-01, a peripherally-restricted oral NLRP3 inhibitor in Phase 1, to Novo Nordisk A/S.
The advancement of VENT-03 into Phase 2 testing represents what the company describes as "a key step in unlocking the tremendous potential of VENT-03 as a pipeline-in-a-product," reflecting its potential applications across multiple disease areas beyond lupus (搜索).